Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

Philips in talks with FDA after new ventilator findings - statement

Published 11/14/2021, 06:35 AM
Updated 11/14/2021, 08:45 AM
© Reuters. FILE PHOTO: Dutch technology company Philips' logo is seen at company headquarters in Amsterdam, Netherlands, January 29, 2019. REUTERS/Eva Plevier/File Photo

AMSTERDAM (Reuters) - Philips, the medical equipment maker that is recalling ventilators due to use of parts containing a potentially hazardous foam, said on Sunday it is in dicussions with U.S. regulators after a new inspection of one of the company's facilities.

Philips in September estimated it will replace up to 4 million vetilators and respiratory devices because of a polyurethane foam part that might degrade and become toxic.

The company has produced 15 million devices using the foam since 2009 but some are not in use.

On Nov. 12, the U.S. Food and Drug Administration (FDA) said that it had obtained new information during inspections of the company's Murraysville, PA facility.

The FDA asked Philips to conduct more tests on the foam used in the recalled ventilators and said the company has not sufficiently demonstrated that other devices containing the foam should not also be recalled. It also said Philips' procedures for design change may not be adequate.

“We will work closely with the FDA to clarify and follow up on the inspectional findings and its recent requests related to comprehensive testing," Philips CEO Frans van Houten said in a statement.

"Until we have concluded these discussions, we are not able to publicly provide further details."

It said it expected to complete its own testing of the foam in the fourth quarter.

The company has been using a replacement silicone-based foam which must now also undergo further safety testing.

The FDA statement said that while it could not be sure, on the basis of what it knows now, that the silicone-based foam being used for repaired products is safe either, it does not recommend patients stop using them, based on a risk-benefit assessment.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Philips has so far put aside 500 million euros ($572.50 million in provisions for recall costs. In October it lowered financial forecasts for the year, citing fallout from the recall and related lawsuits.

(This story corrects to clarify Philips targeting 4 million devices in recall; both polyurethane and silicon foam parts under review)

($1 = 0.8734 euros)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.